Document is current
Any future updates will be listed below
-
Authors
Guijosa, Alberto
Tsakmaklis, Nicholas
Kobs, Margaret
Kofides, Amanda
Guerrera, Maria Luisa https://orcid.org/0000-0002-0730-4678
von Keudell, Gottfried
Branagan, Andrew https://orcid.org/0000-0002-3868-9267
Hunter, Zachary R. https://orcid.org/0000-0002-1689-1691
Treon, Steven P. https://orcid.org/0000-0001-6393-6154
Sarosiek, Shayna https://orcid.org/0000-0002-0075-6735
Castillo, Jorge J. https://orcid.org/0000-0001-9490-7532
- License Information
-
More Information
Article History
Received: 13 November 2025
Revised: 4 December 2025
Accepted: 27 January 2026
First Online: 3 February 2026
Change Date: 11 June 2026
Change Type: Update
Change Details: The following information was missing from the Acknowledgement section: The authors thank the WMR Fund, the Kaplan Family Fund for Waldenström Macroglobulinemia, the Bayer Family Research Fund, the Fred and Michele Brettschneider Family Research Fund, the Deborah Cummins Waldenström Memorial Fund, and the Vanier Family WM Research Fund for their support.
Competing interests
: JJC received research funds or consulting fees from AbbVie, AstraZeneca, BeOne, Cellectar, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, and Schrodinger. SS received research funding or consulting fees from ADC Therapeutics, AstraZeneca, BeOne, Cellectar, and Sobi. SPT received research funding, and/or consulting fees from Abbvie/Pharmacyclics Inc., Janssen Oncology Inc., Beigene Inc., Eli Lilly Pharmaceuticals, Bristol Myers Squibb, and Ono Pharmaceuticals.
: All methods were performed in accordance with the relevant guidelines and regulations governing human subjects research. The study was reviewed and approved by the Dana-Farber Cancer Institute Institutional Review Board (protocol number 25-151). Due to the retrospective nature of the study and the use of previously collected medical record data, the requirement for informed consent was waived.
